Endoscopy Sterilization Market Size & Share 2026-2035

Endoscopy Sterilization Market Size

The global endoscopy sterilization market was valued at USD 1.5 billion in 2025 and is projected to reach USD 2.9 billion by 2035, advancing at approximately 6.7% from 2026 to 2035.

Endoscopy sterilization encompasses the validated cleaning, disinfection, drying, storage, and, where required, terminal sterilization steps used to prepare reusable endoscopes for subsequent patient use. The requirement is operationally demanding because flexible endoscopes combine heat-sensitive materials with narrow, complex channels that must be consistently cleaned, disinfected, dried, and documented. U.S. gastrointestinal endoscopy volume alone exceeds 20 million procedures annually, creating a large recurring need for reliable reprocessing capacity and traceable infection-control practices ^{[1]National Institute of Diabetes and Digestive and Kidney Diseases, niddk.nih.gov}.

Demand is therefore shaped by more than procedure volume. Hospitals and ambulatory facilities are investing in automated endoscope reprocessors (AERs), drying cabinets, traceability software, compatible detergents, and low-temperature sterilization platforms to reduce dependence on variable manual tasks. The commercial opportunity increasingly lies in complete workflow systems rather than in a standalone washer or sterilizer: providers need equipment, chemistry, endoscope-specific connections, documentation, service support, and validated processing instructions that work together.

Procedure growth supports recurring demand, but infection-control risk determines the value assigned to automation. A facility that reduces channel-connection errors, avoids recontamination during storage, and produces usable cycle records can protect throughput while improving compliance. Consequently, consumables and accessories are expected to outpace devices, even though capital systems retain the larger revenue base.

Key Drivers

Rising incidence of hospital-acquired infections

Healthcare-associated infection risk keeps endoscope reprocessing under close clinical and regulatory scrutiny. Flexible endoscopes can contain long channels, valves, and distal-end features that complicate cleaning and drying. Reprocessing failures can therefore have consequences beyond the affected procedure room, including scope quarantines, delayed schedules, corrective training, and reputational exposure. This risk is accelerating adoption of AERs, controlled drying and storage systems, and digital traceability that can demonstrate completion of each required processing step.

Technological advancements in sterilization technologies

Low-temperature technologies are expanding the range of heat-sensitive devices that can be processed without relying on high-temperature steam. Vaporized hydrogen peroxide systems, plasma-based systems, ozone-assisted platforms, and advanced liquid-chemical AERs address distinct needs involving lumen compatibility, cycle duration, materials compatibility, and terminal-sterilization requirements. Suppliers are also reducing error points through automated channel connections, RFID tracking, pass-through configurations, and software that links endoscope identity with cycle records.

Increasing volume of endoscopic diagnostic and therapeutic procedures

Gastroenterology remains the largest source of reprocessing demand, but bronchoscopy, urology, orthopedics, and transesophageal echocardiography broaden the installed base of instruments requiring specialized workflows. Higher procedure volumes increase the economic penalty associated with slow reprocessing turnaround or bottlenecks. Facilities must balance clinical availability with time required for cleaning, high-level disinfection or sterilization, drying, and documentation. This dynamic supports multi-scope AERs, faster validated cycles, and storage solutions that preserve scope readiness between procedures.

Growing investment in healthcare infrastructure and hospital sterilization departments

New hospitals, specialty centers, and expanded endoscopy units require reprocessing capacity as part of their clinical infrastructure. Investments in pass-through AERs, central sterile processing departments, and dedicated clean-side workflows are particularly relevant in regions expanding tertiary-care and diagnostic capacity. The investment case strengthens when equipment can integrate cleaning chemistry, traceability, and service support rather than creating separate documentation and compatibility burdens.

Key Restraints

High costs of advanced sterilization systems

Capital expenditure remains a material barrier, particularly for smaller hospitals, independent ambulatory centers, and facilities operating in markets with constrained reimbursement or procurement budgets. The cost is broader than the purchase price of a sterilizer or AER: installation requirements, dedicated room layouts, chemistry, service contracts, consumables, staff training, and validation protocols can raise the full cost of ownership. Low-volume facilities may continue to rely on existing high-level-disinfection workflows where a new terminal-sterilization platform cannot be economically justified.

Complexity of reprocessing procedures and strict protocol requirements

Automation reduces manual variation but does not eliminate the need for disciplined pre-cleaning, leak testing, loading, channel connection, inspection, drying, storage, and documentation. A single missed step can disrupt the chain of traceability or compromise the outcome of an otherwise validated cycle. Device-specific instructions for use also create compatibility-management burdens, particularly for facilities with mixed endoscope fleets. These constraints favor suppliers that simplify workflows, but they slow implementation where staffing, training, or physical layout is inadequate.

Suppliers that lower the number of manual handoffs can widen adoption even when their systems command a premium. Pass-through architecture, one-time channel connections, automated brushing, and digital records reduce the operational burden that often prevents facilities from realizing the full value of advanced reprocessing equipment. The commercial advantage is likely to accrue to vendors that convert compliance requirements into simpler, repeatable daily practice.

Endoscopy Sterilization Market Segment Analysis

By product

Devices are projected to grow at a 6.45% CAGR through 2035 and remain the market's largest product category. Endoscope sterilization systems generate the greatest device-level demand because they support the core disinfection or terminal-sterilization process. In North America, this subsegment is projected to expand at 5.90%, ahead of drying, storage, and transport systems at 5.30%. Demand for integrated systems is reinforced by the need to process complex flexible endoscopes while retaining evidence of each completed cycle.

Endoscope drying, storage, and transport systems are becoming more important as facilities address the period between reprocessing and reuse. Drying cabinets can reduce the risk that residual moisture compromises the reprocessed state of an endoscope, while controlled storage protects the instrument and supports inventory visibility. Other devices, including cleaning stations and workflow accessories, remain necessary but are expected to grow more slowly.

Consumables and accessories are forecast to advance at 7.23%, exceeding device growth. Enzymatic detergents, peracetic-acid chemistry, compatible connectors, test materials, packaging, and maintenance accessories are tied to procedure activity and installed-equipment use. Their faster growth reflects the recurring nature of reprocessing, as well as the value of validated chemistry-device combinations.

By sterilization method

Hydrogen peroxide sterilization is projected to grow at 6.99% through 2035, the fastest among the principal methods. Its market position is supported by low-temperature processing for heat-sensitive devices and its fit with technology platforms designed for documented, controlled cycles. However, adoption depends on device compatibility, lumen specifications, and facility workflow requirements.

Ethylene oxide sterilization is expected to expand at 6.42% through 2035. Its ability to penetrate complex device configurations remains relevant for instruments with challenging lumens and material constraints. Its operational requirements, including aeration and regulatory controls, can limit its suitability for facilities prioritizing rapid onsite turnaround.

Liquid chemical sterilization is projected to grow at 5.32%. The method remains important where facilities use AER-based high-level disinfection and liquid chemical workflows for flexible endoscopes. Growth is comparatively slower because the market is shifting toward solutions that combine processing effectiveness with reduced manual exposure and more complete traceability. Other sterilization methods are forecast to grow at 4.57%.

By end use

Hospitals are expected to expand at 7.17% through 2035, the highest rate among end-user categories. Their scale, complex procedure mix, emergency caseloads, and sterile-processing requirements support investment in multi-scope AERs, pass-through workflows, drying cabinets, and centrally managed documentation. Hospitals also have the strongest incentive to standardize procedures across multiple departments and sites.

Ambulatory surgical centers are projected to grow at 6.14%. Their need for rapid turnover supports compact and simplified equipment, but capital constraints and lower daily scope volumes can favor targeted investment over comprehensive central-department installations. Other end users are expected to grow at 4.66%, reflecting more limited purchasing scale and less consistent procedural demand.

Hydrogen peroxide's stronger projected growth should not be interpreted as a universal replacement for every method. Endoscope compatibility, channel geometry, turnaround requirements, and facility infrastructure determine the viable technology choice. The market is consequently likely to remain multi-modal, with clinical settings selecting the method that best matches their device mix and compliance burden.

Endoscopy Sterilization Market Regional Analysis

North America accounted for USD 590.08 million in 2025, representing approximately 39.4% of global market revenue. The region is projected to reach USD 1,059.22 million by 2035, at a 5.76% CAGR. The United States generated USD 555.12 million in 2025 and is projected to reach USD 974.77 million by 2035. Its large endoscopy procedure base, established hospital networks, and stringent reprocessing expectations support demand for advanced AERs, low-temperature systems, drying solutions, and traceability infrastructure. Canada is projected to grow faster, at 8.89%, from a smaller installed base.

Europe reached USD 414.20 million in 2025 and is projected to expand at a 6.03% CAGR through 2035. Germany, the UK, France, Spain, Italy, and the Netherlands represent important markets for validated reprocessing workflows. Regulatory compliance, aging demographics, and growing gastrointestinal and respiratory care needs support replacement demand and investment in documented endoscopy-unit processes.

Asia Pacific is projected to record the fastest regional growth, at 8.09%, increasing from USD 400.54 million in 2026 to USD 806.69 million in 2035. China, Japan, India, Australia, and South Korea are central to regional demand. Expansion of hospital infrastructure, rising diagnostic capacity, medical tourism, and a growing procedural base are widening the addressable market. The region also presents varied purchasing conditions, ranging from high-specification tertiary hospitals to facilities seeking compact systems with lower installation requirements.

Latin America is forecast to grow at 7.66%, rising from USD 93.95 million in 2026 to USD 182.53 million by 2035. Brazil, Mexico, and Argentina are supported by healthcare modernization and greater use of minimally invasive procedures, although capital budgets and access to specialist servicing remain uneven.

Middle East and Africa is projected to post a 9.55% CAGR, the highest regional rate from a smaller base, reaching USD 126.36 million by 2035. Saudi Arabia, the UAE, and South Africa are focal markets. Healthcare investment, specialty-center development, and government infection-control initiatives are creating demand for modern reprocessing capacity, particularly in new hospital and diagnostic facilities.

Asia Pacific and Middle East and Africa offer stronger percentage growth because endoscopy capacity and healthcare infrastructure are being built out simultaneously. These markets will not develop uniformly. Large tertiary hospitals may purchase integrated pass-through systems and centralized workflows, while smaller providers may prioritize compact AERs, modular drying systems, and local service availability. Suppliers that can match technology intensity with realistic installation and support requirements are better positioned to convert regional infrastructure spending into sustained demand.

Endoscopy Sterilization Market Share & Competitive Landscape

Competition spans infection-prevention specialists, endoscope original equipment manufacturers, low-temperature sterilization providers, washer-disinfector suppliers, and companies focused on traceability or storage. The five largest participants-STERIS, ASP, Olympus, ECOLAB, and Getinge-collectively accounted for an estimated 54% of global market revenue in 2025. Their position reflects broad product portfolios, installed customer bases, and the ability to connect equipment with chemistry, service, and documentation.

ARC Healthcare Solutions competes through a turnkey flexible-endoscope workflow that combines the PT3 AER, pre-cleaning stations, and HEPA-filtered drying and storage cabinets. Its PT3 system uses three independent disinfection chambers and is designed to process up to nine scopes per hour, emphasizing repeatability and throughput for endoscopy departments ^{[2]ARC Healthcare Solutions, arc-hcs.com},.

ASP is positioned in advanced hydrogen peroxide gas-plasma sterilization. Its August 2024 FDA-cleared ULTRA GI Cycle for STERRAD 100NX with ALLClear Technology extended its focus to duodenoscope processing and compatible PENTAX Medical devices ^{[3]Business Wire, businesswire.com}. AURORA is an emerging pre-commercial competitor rather than an established revenue leader. Its Aqsaniit platform is being developed around cold plasma generated from ionized oxygen, with a stated objective of providing low-temperature processing for flexible endoscopes without conventional chemical residues,.

ECOLAB's Soluscope platform combines AERs, automated pre-cleaning, peracetic-acid chemistry, detergents, and anti-corrosive products. The integrated approach is designed to align equipment and chemistry validation while reducing manual channel-flushing steps. Getinge similarly competes through complete reprocessing architecture, including ED-Flow AERs, pass-through configurations, tracking functions, and sterile-processing products. Its acquisition of Healthmark Industries and Ultra Clean Systems broadened its U.S. infection-control consumables and cleaning-technology footprint,.

H.W. Andersen Products remains a specialized ethylene oxide participant, offering EOGas and Anprolene systems for heat-sensitive flexible endoscopes. Its product positioning centers on terminal-sterilization capability for challenging lumens and integrated aeration,. HUMAN MEDITEK supplies hydrogen peroxide plasma sterilizers with dedicated endoscope modes and compatibility certifications for specified Olympus and PENTAX devices.

Matachana combines low-temperature sterilization equipment with WASSENBURG-branded washer-disinfector and drying solutions, allowing hospitals to source high-level disinfection and terminal-sterilization components through an integrated platform,. MMM Group links washer-disinfectors, drying and storage cabinets, low-temperature sterilizers, and the RUMED360 Endo Admin digital platform to address process documentation and multi-site workflow visibility,.

Olympus occupies a distinctive position as an endoscope OEM with reprocessing equipment, accessories, and service capabilities. Its ETD washer-disinfector portfolio and Sapphire centralized reprocessing model extend its role beyond instrument supply into endoscopy-unit workflow support,. Richard Wolf differentiates through reprocessability-by-design, validated chemical and washer-disinfector compatibility information, sterilization baskets, and staff training resources,.

Steelco's ARES platform combines AERs, liquid-chemical processing options, RFID-enabled workflows, and traceability software. Its one-time connection system is intended to reduce reconnection steps between pre-washing and reprocessing,. STERIS competes through a broad infection-prevention portfolio that includes AERs, liquid chemical sterilization systems, high-level disinfectants, and service support. Its enspire 300 Series AER received FDA clearance in July 2023 for specified flexible endoscope configurations.

Stryker differentiates through Sterizone VP4, which uses vaporized hydrogen peroxide followed by ozone and is cleared for specified multi-channel flexible endoscopes. The system's single preset cycle and broad validated-device compatibility address workflow simplicity and mixed-load processing needs. Tuttnauer targets gastroenterology, respiratory endoscopy, operating-room, and central sterile-processing settings with PlazMax low-temperature hydrogen peroxide and plasma systems that include dedicated endoscope cycles and digital cycle-data management.

Recent Industry Developments

• In August 2024, ASP received FDA clearance for its ULTRA GI Cycle for use in STERRAD 100NX with ALLClear Technology for duodenoscope reprocessing. The clearance also covered compatibility with the PENTAX Medical DEC Duodenoscope, linking low-temperature gas-plasma sterilization with a high-risk flexible-endoscope application.

• HOYA Corporation acquired the remaining 49% stake in Wassenburg Medical in November 2023, making Wassenburg a wholly owned subsidiary. The transaction brought AERs, washer-disinfectors, consumables, and automated pre-cleaning capabilities more directly into the HOYA and PENTAX Medical endoscopy ecosystem.

• Getinge completed the acquisition of Healthmark Industries in the fourth quarter of 2023 and acquired Ultra Clean Systems during 2023. These transactions expanded Getinge's sterile-processing consumables and instrument-cleaning capabilities in the United States.

• STERIS received FDA 510(k) clearance for its enspire 300 Series AER in July 2023. The system is designed to process up to two specified immersible gastrointestinal flexible endoscopes or up to six non-channeled naso-endoscopes.

• Olympus introduced its ETD Endoscope Washer Disinfector in the EMEA region in June 2023. Olympus stated that the ETD Basic and ETD Premium systems provide a 29-minute full reprocessing cycle and reduce resource consumption relative to the preceding generation.

• In September 2024, Olympus launched Sapphire in Melbourne, Australia, as a centralized flexible-endoscope reprocessing service. The facility provides cleaning, disinfection, ethylene oxide sterilization, sterile-barrier packaging, and microbiological test results through the Olympus On-Demand model.